MAPK3 and medulloblastoma: In our study, addition of the above mentioned growth factors to crizotinib or canertinib highlights the strong bypassing potential of HGF in addition to canertinib on medulloblastoma cell viability and downstream signaling effectors Akt and ERK1/2.